Skip to main content
 

As one of the fastest-growing pharmaceutical companies in Türkiye, we use our ethical, human-centric, diverse, and bold vision to provide solutions for unmet medical needs worldwide.

For Healthier GENerations

Who Are We?

As one of the fastest-growing pharmaceutical company in Türkiye, we have been providing solutions worldwide for rare diseases and unmet medical needs since 1998. With our vast range of products, innovative approach, and global team of experts, we continue our efforts within the framework of ethical and scientific principles, aiming to be a significant global player in the pharmaceutical industry and the health brand of the future.

100% Local and
Publicly Traded Company

10 Offices in
7 Countries

25+ Years of Experience in
Rare Diseases

GMP-Certified Manufacturing
Facility and Center

Investor Relations

22.62% of our company was offered to the public at 10.75 TL on August 5, 2021, following high interest and demand from our investors.

GEN shares are traded on Borsa Istanbul (BIST) under the ticker “GENİL” and have continued their steady rise since the day they were offered.

Investor Relations

22.62% of our company was offered to the public at 10.75 TL on August 5, 2021, following high interest and demand from our investors.

GEN shares are traded on Borsa Istanbul (BIST) under the ticker “GENİL” and have continued their steady rise since the day they were offered.

Our Solutions

GEN, with its versatile business model, provides solutions for rare diseases and unmet medical needs worldwide through strong global partnerships.

Additionally, with its state-of-the-art manufacturing facility meeting the highest standards and substantial R&D investments, GEN develops and produces highly demanded and competitive products for the international market.

Products

We Care About Ethics and Compliance

You can send your complaints and feedback to us anonymously. You can click the icon for Ethics and Compliance Feedback form.

Ethics and Compliance Feedback Form

Adverse Reaction
Notification

If you want to report adverse reactions related to our products, you can fill in TÜFAM Adverse Reaction Notification Form and send it to [email protected]

Adverse Reaction Notification Form

Adverse Reaction Notification

If you want to report adverse reactions related to our products, you can fill in TÜFAM Adverse Reaction Notification Form and send it to [email protected]

Adverse Reaction Notification Form

Latest Updates

GEN has signed an important partnership and collaboration agreement with Jaguar Health Inc.

| 2024 | No Comments
GEN has signed an important partnership and collaboration agreement with Jaguar Health.…

GEN initiates Phase 1 study of the first-in-class investigational drug SUL-238

| 2024 | No Comments
GEN initiates Phase 1 study of the first-in-class investigational drug SUL-238 Ankara,…

GEN is on the Fortune 500 Türkiye List!

| 2023 | No Comments
As one of Türkiye's fastest-growing pharmaceutical companies, we are pleased to be…

Latest Updates

2024
March 20, 2024

GEN has signed an important partnership and collaboration agreement with Jaguar Health Inc.

GEN has signed an important partnership and collaboration agreement with Jaguar Health.…
2024
February 22, 2024

GEN initiates Phase 1 study of the first-in-class investigational drug SUL-238

GEN initiates Phase 1 study of the first-in-class investigational drug SUL-238 Ankara,…
2023
September 4, 2023

GEN is on the Fortune 500 Türkiye List!

As one of Türkiye's fastest-growing pharmaceutical companies, we are pleased to be…